The next forum for unraveling FDA off-label marketing rules: State and federal legislatures.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29738523.
- Also identified by DOI 10.1371/journal.pmed.1002564 and PMC identifier 5940176.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a Guest Editorial, Aaron S. Kesselheim and Michael S. Sinha show how federal and state legislation to allow promotion of drugs for non-approved uses threatens to undermine the FDA's public health mission.
Medical subject headings
- Federal Government
- Government Regulation
- Off-Label Use
- State Government
- United States Food and Drug Administration